Kornimate/medical-research-clean huggingface dataset:
study of blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

Conditions: Breast Cancer; Colorectal Cancer; Lung Cancer; Melanoma (Skin); Pancreatic Cancer

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer. purpose: this research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

objectives: primary * to assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups. secondary * to conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy. outline: this is a multicenter study. blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.

Eligibility criteria:
disease characteristics: * diagnosis of 1 of the following advanced metastatic malignancies: * malignant melanoma * lung cancer * breast cancer * pancreatic carcinoma * colorectal cancer * advanced and/or metastatic disease * hormone receptor status not specified patient characteristics: * menopausal status not specified prior concurrent therapy: * not specified

Keywords: stage iv melanoma recurrent melanoma stage iv non-small cell lung cancer recurrent non-small cell lung cancer extensive stage small cell lung cancer recurrent small cell lung cancer stage iv breast cancer recurrent breast cancer male breast cancer stage iii pancreatic cancer stage iv pancreatic cancer recurrent pancreatic cancer stage iv colon cancer recurrent colon cancer stage iv rectal cancer recurrent rectal cancer
relationship of brain natriuretic peptide (bnp) levels to cardiac diagnosis, operation performed, post-operative course and outcome

Conditions: Congenital Heart Disease

Summary: the purpose of this study is to assess brain natriuretic peptide levels to evaluate the relationship of those levels with the diagnosis of congenital cardiac disease, operation performed, post-operative course, and outcome.

three types of natriuretic peptides (np) have been isolated: atrial natriuretic peptide (anp), brain natriuretic peptide (bnp), and c-type natriuretic peptide (cnp). the np family elicits a number of vascular, renal and endocrine effects that help to maintain blood pressure and extracellular fluid volume. these effects are mediated by the specific binding of np to cell surface receptors that have been characterized, purified and cloned from cells of the vasculature, kidney, adrenal gland and brain. there are 3 subtypes of np receptors: type a natriuretic peptide receptor (npra), type b natriuretic peptide receptor (nprb), and type c natriuretic peptide receptor (nprc). all 3 subtypes affect cellular second messenger activity. the literature currently does not define the levels of b-type natriuretic peptide (bnp) in children with congenital heart disease undergoing surgery. the investigator wishes to perform a retrospective chart review to define bnp levels in the pediatric cardiac defect population and to evaluate the relationship of those levels with cardiac diagnosis, operation performed, post-operative course and outcome. the investigator will collect the following information from the medical record: * laboratory: bnp levels, serum ph, lactic acid, co-ox, cbc, chemistry * diagnosis * surgical procedure * incidence of re-operation * length of icu stay * length of hospital stay * complications * length of ventilation (how many days on the ventilator) * medications * cross clamp time * bypass time * echocardiogram data * cardiac catheterization data * vital signs * monitored hemodynamic measures * final outcome (discharged or death)

Eligibility criteria:
inclusion criteria: * congenital heart defect exclusion criteria: * patients without congenital heart defects

Keywords: bnp pediatrics congenital heart disease b-type natriuretic peptide
study evaluating the efficacy and safety of bapineuzumab in alzheimer disease patients

Conditions: Alzheimer Disease

Summary: this is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate alzheimer disease. patients will receive either bapineuzumab or placebo. each patient's participation will last approximately 1.5 years.


Eligibility criteria:
inclusion criteria: * diagnosis of probable alzheimer disease (ad), with mini mental state examination (mmse) score of 16-26, and brain magnetic resonance imaging (mri) consistent with the diagnosis of ad * concurrent use of cholinesterase inhibitor or memantine allowed, if stable * caregiver will participate and be able to attend clinic visits with patient exclusion criteria: * significant neurological disease other than ad * major psychiatric disorder * contraindication to undergo brain mri \[e.g., pacemaker, cerebrospinal fluid (csf) shunt, or foreign metal objects in the body\] * women of childbearing potential

Keywords: antibody immunotherapy
retrospective analysis for the clottriever catheter to investigate safety and effectiveness in the treatment of acute and subacute iliofemoral deep vein thrombosis (dvt)

Conditions: Deep Vein Thrombosis

Summary: the aim of the study is to evaluate the safety and performance of the clottriever catheter in the treatment of patients with symptomatic iliofemoral deep vein thrombosis (dvt)

data from patients in whom the clottriever catheter was used for treatment of iliofemoral dvt was retrospectively collected for up to 6 months after the procedure for evaluation of safety and effectiveness.

Eligibility criteria:
inclusion criteria: * uni or bilateral iliofemoral dvt exclusion criteria: * previously stented in treatment vein
relief: randomized episodic versus long-term suppression experience with famciclovir

Conditions: Recurrent Genital Herpes (RGH)

Summary: this trial will assess whether rgh patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their rgh.


Eligibility criteria:
inclusion criteria: * • patients who are immunocompetent and who have had 4 or more episodes of recurrent genital herpes (rgh) in the last 12 months. * patients with active hsv-2 or hsv-1 infection as confirmed by polymerase chain reaction (pcr). * patients with active symptoms (i.e., itching, burning, tingling, aching, tenderness, rash or pain) associated with a recurrent episode of genital herpes exclusion criteria: * • female patients who are pregnant or breast-feeding. * current, history or suspicion of liver disease or kidney disease. * hiv infected (as confirmed by positive hiv serology). other protocol-defined inclusion/exclusion criteria may apply.

Keywords: recurrent genital herpes (rgh), famciclovir, episodic treatment, suppressive treatment, polymerase chain reaction (pcr).
bleomycin electrosclerotherapy treatment of vascular malformations: a feasibility study

Conditions: Vascular Malformations

Summary: the aim of the best study is to examine the feasibility of assessing patient and clinician reported outcome of a single electrosclerotherapy treatment of vascular malformations. * sclerotherapy = injection of bleomycin into vascular birthmarks to seal off abnormal vascular channels * electroporation = application of an electric field to vessels treated with a handheld needle electrode * electrosclerotherapy = a combination of bleomycin sclerotherapy and electroporation


Eligibility criteria:
inclusion criteria: * new patients presenting with a vascular malformation suitable for bleomycin sclerotherapy treatment * existing patients presenting with a poor response to treatment, performed more than 6 months ago * placement of a needle electrode into the vascular malformation is technically possible * evaluation of response to treatment is possible on photo documentation * patients agreeing to participate in the study * the ability to understand written and spoken english exclusion criteria: * patients not agreeing to participate in the study * pregnancy * breastfeeding * previous high systemic bleomycin exposure (more than 3000 iu) * patients unable to provide written, informed consent * patients in which needle electrode placement is not possible * response to treatment not evaluable by photo documentation * patients unable to speak english
development of the orca communication measure for rett syndrome

Conditions: Rett Syndrome

Summary: this measurement validation study will use qualitative and quantitative methodology to evaluate the observer-reported communication ability measure (orca), to appropriately capture communication abilities in individuals with rett syndrome. the orca measure is a caregiver-reported questionnaire that collects caregiver observations of their child's communication abilities including expressive, receptive and pragmatic communication types. caregivers will participate via phone interviews and online surveys. approximately 270 participants will be enrolled.

this study will develop the observer-reported communication ability measure (orca), originally validated for angelman syndrome, to appropriately capture communication abilities in individuals with rett syndrome. the orca measure is a caregiver-reported questionnaire that collects caregiver observations of their child's communication abilities including expressive, receptive and pragmatic communication. the goal of the study is to generate a validated tool to comprehensively assess communication in rett syndrome and create an important endpoint for use in clinical trials. in phase 1, a hybrid approach to concept elicitation and cognitive testing will occur with caregivers to assess the existing orca measure and evaluate orca content validity. approximately 20 parents/caregivers of individuals with rett syndrome will participate in qualitative in-depth interviews. the orca measure, instructions, recall period, and response choices will be evaluated. in phase 2, psychometric properties including reliability, floor/ceiling effects, construct validity, and test-retest will be evaluated with approximately 250 caregiver-parents of individuals with rett syndrome. caregivers will also complete additional questionnaires to allow comparison between the orca measure and existing measures. analysts will use a variety of statistical methods to evaluate the psychometric properties of the orca measure in rett syndrome.

Eligibility criteria:
inclusion criteria: * parent or caregiver at least 18 years of age, with a female child, age 2 or older, diagnosed with rett syndrome confirmed by a disease-causing mecp2 genetic mutation. * fluency in the english language * currently lives with the child with rett syndrome * ability and willingness to participate in all study activities. * access to a telephone and/or access to a device with internet access that is capable of supporting electronic survey completion exclusion criteria: * parent or caregiver with clinically significant condition or situation that makes them not be suitable for the study, in the opinion of research staff. * parent or caregiver of a child with rett syndrome who also has another diagnosis in addition to rett syndrome.

Keywords: orca communication duke mecp2 rsrt
clinical outcomes of triple combination therapy in severe cystic fibrosis disease.

Conditions: Cystic Fibrosis

Summary: this is an observational study of people with severe cystic fibrosis that are eligible for vertex's triple combination therapy through its expanded access. pulmonary health, intestinal health, and the overall health of individuals will be tracked for a year to see how effective triple combination therapy is in these people with severe cystic fibrosis disease.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cystic fibrosis * ability to reproducibly perform spirometry (according to ats criteria) * physician decision to treat with tct through the eap program * ability to understand and sign a written informed consent or assent and comply with the requirements of the study exclusion criteria: * history of hypersensitivity to vx 445, vx 659, tezacaftor and/or ivacaftor * any acute lower respiratory symptoms treated with oral, inhaled or iv antibiotics or systemic corticosteroids within the 2 weeks prior to visit 1. * major or traumatic surgery within 12 weeks prior to visit 1. * initiation of any new chronic therapy (e.g., ibuprofen, pulmozyme®, hypertonic saline, azithromycin, tobi®, cayston®) within 4 weeks prior to visit 1. * use of an investigational agent within 28 days prior to visit 1. * history of lung or liver transplantation or listing for organ transplantation.
chronic transplant glomerulopathy and regulation of expression of ephrin b1

Conditions: Kidney Transplantation

Summary: the principal purpose is the study of the regulation of the expression of ephrin-b1 by immunofluorescence in kidney biopsies of patients with chronic transplant glomerulopathy (ctg) compared to biopsies prior to the ctg, in same patients. level of fluorescence in ctg biopsy will be the experimental reference value.

chronic transplant glomerulopathy (ctg) is a specific lesion of kidney transplantation and a poor prognostic factor affecting transplant survival. diagnosis remains only microscopic and lesions are irreversible. recent studies prove that there is a strong correlation between ctg and antibody mediated rejection (amr) with a possible link with chronic aggression of the endothelial cell. however, for unknown reason, all amr does not lead to a ctg. our recent data on mice demonstrated that ephrin-b1 is expressed in the glomerular endothelial cells and knockout mice for the gene encoding ephrin-b1 develop progressively ultrastructural glomerular lesions close to modifications observed in ctg, as well as proteinuria and chronic renal failure, suggesting that ephrin b1 could participate to ctg. moreover, in a preliminary study on human kidney transplant biopsy we observed decrease in ephrin-b1 immunofluorescence on glomerulus when ctg, even in low grade. these data, and ultrastructural modifications in knock out (ko) mice suggest that early regulation of kidney expression of ephrin-b1 in the glomerulus may occur during the process leading to the ctg as antibody-mediated kidney rejection (amr). the purpose of the study is to determinate if ephrin-b1 expression is modified in ctg.

Eligibility criteria:
inclusion criteria: * kidney transplant patient for whom renal biopsies are stored in the "collection of the university hospital toulouse" (collection n° dc-2009-989) and who received information on the purpose of the study, use of biopsies and who has not manifested any opposition. * kidney transplant patient with iterative biopsies with at least: post-surgery biopsy d0 (or early post-transplant biopsy d7 and at least one biopsy protocol. - age\> 18 years case group: - kidney transplant patient, followed up by "organ transplant unity" of chu toulouse, with antecedent of cmr progressing to ctg between 2006 and 2013. control group: - kidney transplant patient, followed up by "organ transplant unity" of chu toulouse, with antecedent of cmr without progressing to ctg between 2006 and 2013 exclusion criteria: * patient with uncontrolled hypertension - patient with diabetes mellitus - * patient treated or who was treated with mtor inhibitor - recurrence of the initial glomerular pathology - de novo glomerulopathy - patient including in another study with an exclusion period still going

Keywords: chronic transplant glomerulopathy antibody mediated rejection ephrin-b1
attitudes and unmet needs among type 2 diabetes patients

Conditions: Type 2 Diabetes

Summary: the main purpose of this study is to explore experiences and understand the unmet needs of people with type 2 diabetes (t2d) among those who are being managed with basal insulin and those who are insulin naïve in order to understand perspectives for a once weekly insulin option; including any potential barriers to being managed with insulin therapy overall. study participants will be recruited to complete a 15-minute self-administered online survey.


Eligibility criteria:
inclusion criteria: 1. informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. male or female, age above or equal between 18 to 65 years at the time of signing informed consent. 3. diagnosed with t2d and currently treating t2d with at least one medication 4. insulin user that is not using insulin pump 5. lives in a target country exclusion criteria: 1. previous participation in this study. participation is defined as having given informed consent in this study 2. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation 3. does not meet inclusion criteria requirements
willingness to participate in a trial comparing standard genetic counseling versus personalized genetic counseling

Conditions: Li-Fraumeni Syndrome

Summary: this study evaluates patients willingness to participate in a trial comparing standard genetic counseling versus personalized genetic counseling. collecting information from patients may help researchers learn why patients may or may not take part in the future study that compares standard genetic counseling to personalized genetic counseling.

primary objective: i. to evaluate patients' willingness to participate in a future randomized trial comparing standard genetic counseling versus personalized genetic counseling based on li-fraumeni syndrome patient reported outcome (lfspro) shinyapp data. outline: patients complete a questionnaire over 15-20 minutes. patients positive for a tp53 mutation complete an additional questionnaire over 15-20 minutes within 1 month after test results.

Eligibility criteria:
inclusion criteria: * individuals age 15 or older or parent/guardian of a patient younger than 15 years (if age 15-17, the patient will provide assent and parent/guardian will provide consent), pregnant women will also be allowed to participate * english fluency * receive genetic counseling specifically for tp53 genetic testing and who consent to undergo tp53 genetic testing or individuals whose genetic testing indicates a tp53 germline mutation exclusion criteria: * individuals who are non-english speaking * individuals having low suspicion for a tp53 germline mutation during pretest counseling and test negative for a tp53 mutation
electrolyte balance effects of sterofundin versus normal saline in diabetic ketoacidosis

Conditions: Treatment Diabetic Ketoacidosis, Electrolyte Balance Effects

Summary: the goal of this prospective single centered randomized control trial is to compare the electrolyte balance effects between sterofundin and normal saline in diabetic ketoacidosis patients. the main questions it aims to answer are: i. is there any difference in duration of bicarbonate (hco3-) to reach equal or more than 15mmol/l from the initial blood taking in between sterofundin and ns fluid use in dka patients? ii. is there any difference in the level of post-infusion serum sodium (na+) between sterofundin and ns fluid use in dka patients? iii. is there any difference in the level of post-infusion serum potassium (k+) between sterofundin and ns fluid use in dka patients? patients will be randomized in a 1:1 ratio to receive iv sterofundin (intervention) or iv normal saline (standard care). the patient will have the respective fluid regime as the main fluid therapy during the first 24 hours of icu stay. if patients were randomized to the control arm, the fluid regime for the first 24 hours in icu will be normal saline. if patients were randomized to the interventional arm, the main fluid therapy during the first 24 hours of icu stay will be sterofundin.


Eligibility criteria:
inclusion criteria: * dka. * aged ≥ 18 years old. * patients admitted to icu \< 12 hours after initial fluid resuscitation from emergency department/ ward. exclusion criteria: * end stage renal failure * heart failure * started treatment of sodium bicarbonate infusion prior to icu admission * known allergy to sterofundin
does laparoscopic sleeve gastrectomy lead to barrett's esophagus, 5-year esophagogastroduodenoscopy findings: a retrospective cohort study

Conditions: Barrett Esophagus

Summary: introduction laparoscopic sleeve gastrectomy (lsg) is one of the most prevalent approaches to tackle obesity and its co-morbidities. the main complication following the lsg is gastro-esophageal reflux disease (gerd), with most patients developing worsening symptoms of gerd, and a small number progressing to barrett's esophagus. this retrospective analysis aims to assess the rate of gerd pre- and post- lsg as well as the rate of progression to barrett's. methods data was collected from 1639 patients. 92 patients fit our inclusion criteria. data was then analyzed and summarized against similar literature


Eligibility criteria:
inclusion criteria: * patients eligible to sleeve gastrectomy that had an egd pre and 5 years post-op exclusion criteria: * missing or implausible data, had multiple surgeries, and suffered from the common post-sleeve complications, such as leaks, strictures and hiatal hernias
sleep and nocturnal melatonin in adults with attention deficit hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study will investigate the effects of methylphenidate on sleep in adults with attention deficit/ hyperactivity disorder (adhd) using polysomnographic parameters.

previous studies in children with attention deficit/ hyperactivity disorder (adhd) have described the effect of stimulants on sleep patterns. however the data on adults with adhd is sparse. the aim of this study is to investigate the effects of methylphenidate on sleep in adults with adhd using polysomnographic parameters.

Eligibility criteria:
inclusion criteria: * adhd according to dsm-iv criteria * positive asrs questionnaire exclusion criteria: * brain damage * brain encephalopathy * borderline iq * affective disorder

Keywords: adhd adult